The study of impact on PFS of Entecavir combined with local treatment

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-OCC-11001604

Enrollment

Unknown

Registered

2011-08-29

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

1:interventionai treatment of hcc

2:interventionai treatment of hcc+ Entecavir

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients of HCC of Age more than 18 years old and less than 70 years old; 2. HBsAg positive, HBeAg positive or negative; 3. ALB >=32 g/L; 4. TBil<=51.3umol/L; 5. ALT<=2 ULN; 6. before enrollment 1 year had not received antiviral nucleoside drugs treatment; 7. histology compared case should finish operation before 1 July, 2011, and not received antiviral nucleoside drugs treatmen after operation.

Exclusion criteria

Exclusion criteria: 1. Known for allergy with entecavir accessories; 2. infection with HIV and HCV; 3. Renal insufficiency; 4. Decompensated liver function; 5. Portal vein tumor thrombus; 6. Pregnant women.

Design outcomes

Primary

Measure	Time frame
development of cancer;	—

Secondary

Measure	Time frame
HBV-DNA;	—

Countries

China

Contacts

Public Contacthai-yan wang

tiankonghaiyan@yahoo.com.cn+86 010-83997109

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026